Bryostatin 1 | CAS#83314-01-6 | PKC modulator

MedKoo Cat#: 561548 | Name: Bryostatin 1

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bryostatin 1 is a potent Protein Kinase C modulator isolated from the bryozoan Bugula neritina.

Chemical Structure

Bryostatin 1

CAS#83314-01-6

Theoretical Analysis

MedKoo Cat#: 561548

Name: Bryostatin 1

CAS#: 83314-01-6

Chemical Formula: C47H68O17

Exact Mass: 904.4457

Molecular Weight: 905.04

Elemental Analysis: Chemical Formula: C47H68O17 Exact Mass: 904.4457 Molecular Weight: 905.0440 Elemental Analysis: C, 62.37; H, 7.57; O, 30.05

Price and Availability

Size	Price	Availability	Quantity
10µg	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Bryostatin 1; Bryostatin-1; Bryostatin1; NSC-339555; NSC 339555; NSC339555;

IUPAC/Chemical Name

(2E,4E)-2,4-Octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-((1R)-1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo-(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester

InChi Key

MJQUEDHRCUIRLF-TVIXENOKSA-N

InChi Code

InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1

SMILES Code

CCC/C=C/C=C/C(O[C@@H](/C(C[C@@](O1)([H])C[C@H]([C@H](O)C)O2)=C/C(OC)=O)[C@]1(O)C(C)(C)/C=C/[C@@](O3)([H])C/C(C[C@@]3([H])C[C@@](O4)(O)C(C)(C)[C@@H](OC(C)=O)C[C@@]4([H])C[C@@H](O)CC2=O)=C\C(OC)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Bryostatin 1 binds to the isolated C1 domain of Munc13-1 and the full-length Munc13-1 protein with Kis of 8.07 nM and 0.45 nM, respectively.

In vitro activity:

Results show that bryostatin-1 (100, 200 nM) treatment can suppress cell proliferation and induce G1 cell cycle arrest in PLC/PRF/5 and SMCC7721 cell. This study also found a significant inhibitory action of bryostatin-1 (100, 200 nM) on CyclinD1 activity in PLC/PRF/5 cells, and bryostatin-1 can promote ubiquitination-dependent protein degradation of CyclinD1 in PLC/PRF/5 cells. Western blot results confirmed that the active form phospho-GSK3β Tyr216 expression was increased significantly after bryostatin-1 treatment. Activation of GSK3β might be responsible for bryostatin-1 induced cyclinD1 degradation and cell cycle arrest. Taken together, bryostatin-1 may inhibit HCC cells proliferation by promoting cyclinD1 proteolysis and inducing cell cycle arrest. Reference: Biochem Biophys Res Commun. 2019 May 7;512(3):473-478. https://pubmed.ncbi.nlm.nih.gov/30904158/

In vivo activity:

When treated with two doses of 20 µg/kg Bryostatin-1, APOE4 injured mice had significantly less TNF-α, fewer FLJC + cells, and fewer activated IBA1 + cells at 1 DPI in the cortex than APOE4 injured mice treated with control PBS. These data suggest that Bryostatin-1 may be a potent treatment option for improving cellular outcomes in injured APOE4 carriers (Fig. 8A–E). Reference: Sci Rep. 2020 Nov 16;10(1):19919. https://pubmed.ncbi.nlm.nih.gov/33199792/

Preparing Stock Solutions

The following data is based on the product molecular weight 905.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ly C, Shimizu AJ, Vargas MV, Duim WC, Wender PA, Olson DE. Bryostatin 1 Promotes Synaptogenesis and Reduces Dendritic Spine Density in Cortical Cultures through a PKC-Dependent Mechanism. ACS Chem Neurosci. 2020 Jun 3;11(11):1545-1554. doi: 10.1021/acschemneuro.0c00175. Epub 2020 May 21. PMID: 32437156; PMCID: PMC7332236. 2. Wang J, Wang Z, Sun Y, Liu D. Bryostatin-1 inhibits cell proliferation of hepatocarcinoma and induces cell cycle arrest by activation of GSK3β. Biochem Biophys Res Commun. 2019 May 7;512(3):473-478. doi: 10.1016/j.bbrc.2019.03.014. Epub 2019 Mar 20. PMID: 30904158. 3. Giarratana AO, Zheng C, Reddi S, Teng SL, Berger D, Adler D, Sullivan P, Thakker-Varia S, Alder J. APOE4 genetic polymorphism results in impaired recovery in a repeated mild traumatic brain injury model and treatment with Bryostatin-1 improves outcomes. Sci Rep. 2020 Nov 16;10(1):19919. doi: 10.1038/s41598-020-76849-x. PMID: 33199792; PMCID: PMC7670450. 4. Cogram P, Alkon DL, Crockford D, Deacon RMJ, Hurley MJ, Altimiras F, Sun MK, Tranfaglia M. Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice. Sci Rep. 2020 Oct 22;10(1):18058. doi: 10.1038/s41598-020-74848-6. PMID: 33093534; PMCID: PMC7581799.

In vitro protocol:

In vivo protocol:

1. Giarratana AO, Zheng C, Reddi S, Teng SL, Berger D, Adler D, Sullivan P, Thakker-Varia S, Alder J. APOE4 genetic polymorphism results in impaired recovery in a repeated mild traumatic brain injury model and treatment with Bryostatin-1 improves outcomes. Sci Rep. 2020 Nov 16;10(1):19919. doi: 10.1038/s41598-020-76849-x. PMID: 33199792; PMCID: PMC7670450. 2. Cogram P, Alkon DL, Crockford D, Deacon RMJ, Hurley MJ, Altimiras F, Sun MK, Tranfaglia M. Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice. Sci Rep. 2020 Oct 22;10(1):18058. doi: 10.1038/s41598-020-74848-6. PMID: 33093534; PMCID: PMC7581799.

1: Lee Y, Phat C, Hong SC. Structural diversity of marine cyclic peptides and their molecular mechanisms for anticancer, antibacterial, antifungal, and other clinical applications. Peptides. 2017 Sep;95:94-105. doi: 10.1016/j.peptides.2017.06.002. Epub 2017 Jun 10. Review. PubMed PMID: 28610952. 2: Russo P, Kisialiou A, Lamonaca P, Moroni R, Prinzi G, Fini M. New Drugs from Marine Organisms in Alzheimer's Disease. Mar Drugs. 2015 Dec 25;14(1):5. doi: 10.3390/md14010005. Review. PubMed PMID: 26712769; PubMed Central PMCID: PMC4728502. 3: Irie K, Yanagita RC. Synthesis and biological activities of simplified analogs of the natural PKC ligands, bryostatin-1 and aplysiatoxin. Chem Rec. 2014 Apr;14(2):251-67. doi: 10.1002/tcr.201300036. Epub 2014 Feb 20. Review. PubMed PMID: 24677503. 4: Sun MK, Alkon DL. The "memory kinases": roles of PKC isoforms in signal processing and memory formation. Prog Mol Biol Transl Sci. 2014;122:31-59. doi: 10.1016/B978-0-12-420170-5.00002-7. Review. PubMed PMID: 24484697. 5: Kollár P, Rajchard J, Balounová Z, Pazourek J. Marine natural products: bryostatins in preclinical and clinical studies. Pharm Biol. 2014 Feb;52(2):237-42. doi: 10.3109/13880209.2013.804100. Epub 2013 Sep 13. Review. PubMed PMID: 24033119. 6: Abraham I, El Sayed K, Chen ZS, Guo H. Current status on marine products with reversal effect on cancer multidrug resistance. Mar Drugs. 2012 Oct;10(10):2312-21. doi: 10.3390/md10102312. Epub 2012 Oct 19. Review. PubMed PMID: 23170086; PubMed Central PMCID: PMC3497025. 7: Irie K, Yanagita RC, Nakagawa Y. Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ. Med Res Rev. 2012 May;32(3):518-35. doi: 10.1002/med.20220. Epub 2010 Nov 9. Review. PubMed PMID: 22539107. 8: Ruan BF, Zhu HL. The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development. Curr Med Chem. 2012;19(16):2652-64. Review. PubMed PMID: 22506770. 9: Sánchez-Duffhues G, Vo MQ, Pérez M, Calzado MA, Moreno S, Appendino G, Muñoz E. Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs. Curr Drug Targets. 2011 Mar 1;12(3):348-56. Review. PubMed PMID: 20955147. 10: von Schwarzenberg K, Vollmar AM. Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy. Cancer Lett. 2013 May 28;332(2):295-303. doi: 10.1016/j.canlet.2010.07.004. Epub 2010 Jul 31. Review. PubMed PMID: 20673697. 11: Gonelli A, Mischiati C, Guerrini R, Voltan R, Salvadori S, Zauli G. Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. Mini Rev Med Chem. 2009 Apr;9(4):498-509. Review. PubMed PMID: 19356127. 12: Smith AB 3rd, Wuest WM. Evolution of multi-component anion relay chemistry (ARC): construction of architecturally complex natural and unnatural products. Chem Commun (Camb). 2008 Dec 7;(45):5883-95. doi: 10.1039/b810394a. Epub 2008 Sep 30. Review. PubMed PMID: 19030533; PubMed Central PMCID: PMC2769507. 13: Zhang JY, Fu LW. [Advance of several types of important marine antitumor drugs]. Yao Xue Xue Bao. 2008 May;43(5):435-42. Review. Chinese. PubMed PMID: 18717327. 14: Singh R, Sharma M, Joshi P, Rawat DS. Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med Chem. 2008 Aug;8(6):603-17. Review. PubMed PMID: 18690825. 15: Fährmann M. Targeting protein kinase C (PKC) in physiology and cancer of the gastric cell system. Curr Med Chem. 2008;15(12):1175-91. Review. PubMed PMID: 18473812. 16: Banerjee S, Wang Z, Mohammad M, Sarkar FH, Mohammad RM. Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod. 2008 Mar;71(3):492-6. doi: 10.1021/np0705716. Epub 2008 Feb 27. Review. PubMed PMID: 18302335. 17: Le Tourneau C, Raymond E, Faivre S. Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr Pharm Des. 2007;13(33):3427-39. Review. PubMed PMID: 18045196. 18: Sun MK, Alkon DL. Bryostatin-1: pharmacology and therapeutic potential as a CNS drug. CNS Drug Rev. 2006 Spring;12(1):1-8. Review. PubMed PMID: 16834754. 19: Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC. Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J. 2005 Sep;82(9 Suppl):S155-60. Review. PubMed PMID: 16619692. 20: Piel J. Bacterial symbionts: prospects for the sustainable production of invertebrate-derived pharmaceuticals. Curr Med Chem. 2006;13(1):39-50. Review. PubMed PMID: 16457638.